Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-016 in HMA-failed Intermediate/High-risk MDS (China) Phase I/II
CTR20202528Phase 2Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eltanexor in myelodysplastic syndrome (MDS), sponsored by Karyopharm Therapeutics Inc.. Started Dec 2020; status: terminated.
02
Drugs
eltanexor
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20202528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202528.